JPRN-UMIN000035232招募中未知
A phase II clinical trial of neoadjuvant chemoradiation therapy for pancreatic ductal adenocarcinoma - A phase II clinical trial of neoadjuvant chemoradiation therapy for pancreatic ductal adenocarcinoma
Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University0 个研究点目标入组 50 人开始时间: 2018年12月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 86years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with other active cancers 2) Patients who can not take medicine orally 3) Patients with severe allergies 4) Patients with watery diarrhea 5) Patients with severe co-morbid disease 6) Patients seems inadequate for this study by investigator(s)
研究者
相似试验
招募中
2 期
A clinical phase-II trial of neoadjuvant chemoradiotherapy with S-1 and Gemcitabine for locally advanced pancreatic cancer (PerSeUS-GP02)ocally advanced pancreatic cancerJPRN-UMIN000010435PerSeUS: Perpetual Study estimated-by United Sections in gifu40
已完成
2 期
A clinical phase-II trial of neoadjuvant chemoradiation therapy using S-1 for locally advanced pancreatic cancer (PerSeUS-GP-01)ocally advanced pancreatic cancerJPRN-UMIN000002176PerSeUS-GP40
尚未招募
1 期
A phase II clinical trial of neoadjyvant chemoradiation therapy using Gemcitabine combined with IMRT for borderline resectable pancreatic cancerborderline resectable pancreatic cancerJPRN-UMIN000010113Hepato-pamcreato-biliary Surgery and Transplantation, Graduate School of Medicine and Faculty of Medicine KyotoUniversity37
尚未招募
不适用
Phase 2 clinical study of neoadjuvant chemotherapy for HER2-negative primary breast cancer patients using dose dense nab-paclitaxel followed by dose dense Epirubicin and cyclophosphamideHER2 negative primary breast cancerJPRN-UMIN000019787Dept of breast oncology50
已完成
2 期
A phase II trial of Neoadjuvant and adjuvant chemotherapy with Gemcitabine and TS-1 combination for patients with locally advanced pancreatic cancerpancreatic cancerJPRN-UMIN000005578Chiba study group of adjuvant chemotherapy for pancreatic cancer45